INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/BioPharma Dive
Back to Newsroom
🏢Organization Dossier

BioPharma Dive

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

13 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Markets & Equities 20 Nov 2026, 08:00 PM IST

U.S. Alarm Grows Over China’s Grip on Drug Supply Chains

Washington is confronting fresh warnings that China’s expanding role in early-stage drug development and pharmaceutical supply chains could give Beijing outsized leverage over the global biopharma industry. The concern, highlighted in recent reporting and a U.S. panel warning, is not that China already dominates finished medicines, but that it is steadily building control over the upstream inputs and innovation pipeline that underpin future drug production.

By RDU Global Wire5 min read
Frontier AI & Machine Learning10 Oct 2026, 01:28 AM IST

Chai Discovery Wins GSK Deal, Extending Pharma Run to Six Partnerships in Nine Months

AI drug-discovery startup Chai Discovery has secured a collaboration with GSK after what the companies described as successful wet-lab validation, marking the company’s sixth pharmaceutical partnership in the past nine months. The deal underscores how quickly leading drugmakers are moving from evaluating generative AI models to signing commercial collaborations when early laboratory results appear credible.

6 min readRead →
Global Markets & Equities05 Nov 2026, 08:00 PM IST

Boehringer Returns to Sino Biopharma in $7.4 Billion Cancer Pact

Boehringer Ingelheim has struck a new oncology partnership with Sino Biopharma, reviving a relationship that now carries a headline value of up to $7.4 billion. The deal centers on preclinical bispecific T-cell engagers and antibody-drug conjugates, underscoring how large drugmakers are still willing to pay for early-stage cancer assets with long-dated optionality. The agreement adds another major cross-border licensing transaction to a market already defined by capital discipline, pipeline replenishment and intense competition for differentiated oncology platforms. For investors, the structure signals both the scale of demand for next-generation cancer modalities and the long development runway that will determine how much of the deal value ultimately becomes payable.

6 min readRead →
Global Markets & EquitiesJust now (07:03 PM IST)

Sanofi Pays Regeneron $1 Billion Upfront to Deepen Drug Alliance and Reignite R&D

Sanofi has agreed to pay Regeneron $1 billion upfront in a broadened collaboration that could be worth as much as $8 billion, extending one of the biopharma sector’s most productive partnerships. The deal gives Sanofi access to four early-stage assets and comes alongside a legal settlement, underscoring both the commercial value of the alliance and the strategic urgency to refresh each company’s pipeline.

6 min readRead →
Frontier AI & Machine Learning18 Oct 2026, 02:00 PM IST

Beijing Moves to Tighten Control Over AI Exports as U.S. Rivalry Intensifies

China is weighing tighter export controls on artificial intelligence technologies as it seeks to manage security risks and preserve leverage in its escalating technology rivalry with the United States. The proposed restrictions would add another layer of scrutiny to a sector already under pressure from U.S. chip curbs, investment limits and broader efforts to contain China’s access to advanced computing tools.

5 min readRead →
Global Markets & Equities15 Oct 2026, 11:54 PM IST

FDA Signals Stricter, More Predictable Rare Disease Drug Review Framework

The U.S. Food and Drug Administration’s new leadership is moving to reshape how rare disease therapies are evaluated, with an emphasis on consistency, predictability and a more structured approval pathway. The initiative could materially affect drug developers, investors and patients by narrowing the discretion that has long defined this corner of the regulatory process.

5 min readRead →
Global Markets & Equities15 Oct 2026, 02:39 PM IST

FDA Moves to Tighten Rare-Disease Drug Reviews as New Leadership Seeks Consistency

The U.S. Food and Drug Administration is advancing a new rare-disease framework that could reshape how experimental treatments are designed, reviewed and approved. The initiative signals a shift toward greater consistency and broader evidentiary standards, a move that may raise the bar for developers while potentially improving regulatory predictability.

6 min readRead →
Global Economy & Central Banks20 Nov 2026, 08:00 AM IST

Banking Outages Reopen the Cash Question as Advisors Urge Diversification

A spate of recent banking outages is prompting consumers and businesses to reconsider how much physical cash they should keep on hand. Top financial advisers say the answer is not to abandon digital payments, but to diversify access to money so households can function when cards, apps or bank systems fail.

5 min readRead →
Clean Energy & Climate Transition17 Nov 2026, 08:00 PM IST

Scientists Identify Giant New Fungus in China, Raising Fresh Questions for Biodiversity Research

Researchers in China have described a newly identified giant fungus that can grow to roughly 20 inches tall, adding an unusual species to the scientific record and underscoring how much of the planet’s fungal diversity remains undocumented. The discovery, reported by mycologists working in Yunnan, is drawing attention not for any direct industrial use, but for what it reveals about the hidden ecological complexity of forests and soils that underpin climate resilience.

6 min readRead →
National Governance & Policy16 Nov 2026, 02:00 PM IST

National Zoological Park Hosts 21st Sunday Bird Walk to Advance Citizen Science and Biodiversity Documentation

The National Zoological Park in New Delhi marked the 21st edition of its Sunday Bird Walk, positioning the initiative as a practical platform for citizen science and biodiversity documentation. The event underscores a growing policy emphasis on public participation in environmental monitoring, especially in urban ecosystems where data gaps remain significant.

6 min readRead →
Markets, IPOs & Wealth16 Nov 2026, 02:00 PM IST

Indian New-Age Tech Listings Redefine Scale as Market Caps, Revenues Diverge

India’s listed new-age tech companies have moved from speculative market darlings to a more mature, closely scrutinised cohort, with market capitalisation, revenue growth and profitability now being judged in tandem. The latest tracker underscores how public markets are rewarding operational discipline over narrative alone, even as the sector remains one of the most closely watched in Indian equities.

5 min readRead →
World Politics & Diplomacy15 Nov 2026, 08:00 AM IST

Trump Administration Diverts Health Aid, Defying Congress and Squeezing Low-Income Countries

The Trump administration is moving to redirect or withhold billions of dollars in U.S. global health funding, according to reporting that says the effort would undercut congressional spending plans and sharply reduce support for low-income countries. The shift would affect family planning, maternal health and broader aid programs that have long been central to U.S. diplomacy and development policy.

5 min readRead →
Banking, Fintech & Insurance13 Nov 2026, 08:00 PM IST

Sensex, Nifty Turn Choppy as Heavyweights Diverge; Hind Zinc, SBI and Force Motors Draw the Most Action

Indian equities were volatile in late trade on Thursday as benchmark indices wobbled under mixed sectoral pressure, with select heavyweights cushioning losses even as broader sentiment stayed cautious. Asian Paints, SBI, Tata Motors, HUL and Maruti Suzuki led the gainers on the Sensex, while ONGC, Axis Bank, Mahindra & Mahindra, Bajaj Auto and Hero MotoCorp were among the major laggards.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside BioPharma Dive: